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ORIGINAL ARTICLE
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prospective long-term follow up
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Abstract
Objective. Atrophic gastritis (AG) is a risk condition for gastric cancer and type I gastric carcinoids. Recent studies assessing
the overall risk of gastric cancer and carcinoids in AG at long-term follow up are lacking. This study aimed to investigate in a
prospective cohort of AG patients the occurrence of gastric cancer and carcinoids at long-term follow up.Methods. A total of
200 AG patients from a prospective cohort (67% female, median age 55 years) with a follow up of 7.5 (range: 4–23.4) years
were included. Inclusion criteria were presence of AG and at least one follow-up gastroscopy with biopsies at ‡4 years after AG
diagnosis. Follow-up gastroscopies at 4-year intervals were performed. Results. Overall, 22 gastric neoplastic lesions were
detected (crude incidence 11%). Gastric cancer was diagnosed in four patients at a median follow up of 7.2 years (crude
incidence 2%). Eleven type I gastric carcinoids were detected at a median follow up of 5.1 years (crude incidence of 5.5%). In
seven patients, six low-grade and one high-grade dysplasia were found. The annual incidence rate person-year were 0.25%
(95% confidence interval [CI]: 0.067–0.63%), 0.43% (95% CI: 0.17–0.89%), and 0.68% (95% CI: 0.34–1.21%) for gastric
cancer, dysplasia, and type I-gastric carcinoids, respectively. The incidence rates of gastric cancer and carcinoids were not
different (p = 0.07).Conclusion.This study shows an annual incidence rate of 1.36% person-year for gastric neoplastic lesions
in AG patients at long-term follow up. AG patients are similarly exposed to gastric cancer and type I gastric carcinoids.
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Introduction
Atrophic gastritis (AG) is characterized by the loss of
gastric glands replaced by connective tissue or glan-
dular structures inappropriate for location giving arise
to nonmetaplastic or metaplastic atrophy and – as a
consequence – to hypochlorhydria and hypergastri-
nemia [1]. Late-stage AG is often associated with
pernicious anemia [2]. AG is considered a precursor
condition for gastric cancer [3,4]. At follow-up per-
iods ranging from 1 to 16 years, a varying progression
rate of AG to gastric cancer up to 2% per year has
been reported [5–7]. A recent systematic review
showed, in AG patients with pernicious anemia, a
pooled gastric cancer incidence rate of 0.3% person-
year and an estimated sevenfold relative risk of gastric
cancer [8]. Gastric cancer is still the fourth most
common cancer worldwide and the second cause of
cancer-related death [9]. Gastric carcinogenesis prob-
ably involves a multistep progression fromHelicobacter
pylori-related chronic inflammation, to atrophy, intes-
tinal metaplasia, dysplasia, and, finally, intestinal-type
gastric cancer [3]. In parallel, the concept of “gastritis
of the carcinoma phenotype” proposes that the
corpus-predominant gastritis increases the risk of
gastric cancer [10–12], likely due to changes in the
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intragastric milieu as increased pH, reduced ascorbic
acid, and scavenging of nitrites and other potential
carcinogenic substances [13,14].
In patients with AG, type I gastric carcinoids may
also arise. These tumors are well differentiated with
lowproliferative index andagenerallybenignbehavior,
and constitute up to 80% of all gastric carcinoids
[15–17]. A major pathogenetic factor for type I gastric
carcinoids is hypergastrinemia due to AG.Gastrin acts
as a growth factor for enterochromaffin-like cells,
which in AG are chronically induced to proliferate,
and, through a multistep process passing from hyper-
plasia to dysplasia, carcinoid may develop [17–19].
Data on long-term incidence of type I gastric carci-
noids are scanty [20–22]. A recent cohort study
reported an annual incidence rate of 0.4% for type I
gastric carcinoids [23], whereas an older study
reported an annual incidence rate of 2%, observing
8 new cases of type I gastric carcinoids in 416 patient-
years [21]. In the above-cited study, pernicious anemia
waspresent in almost 50%ofpatientswith type I gastric
carcinoids [23], whereas previous studies exclusively
included patients with this condition [21,22,24–26].
In patients with AG, the need and cost-effectiveness
of regular endoscopic follow up for gastric cancer
surveillance is not definitely established. Recent
European guidelines recommend a scheduled surveil-
lance for gastric cancer for those AG patients who
have extensive – that is, both antrum and gastric
body – AG or intestinal metaplasia [27]. In a previous
study, a follow-up interval of 4 years after diagnosis
was shown to be satisfactory for detection of potential
neoplastic lesions in AG patients [28]. IN regard to
surveillance for type I gastric carcinoids, indications
are even more uncertain. A recent study on endo-
scopic management of these tumors, reported that for
AG patients without recurring type I gastric carci-
noids, endoscopic controls might be planned yearly in
the early follow up but can probably become less
intensive with endoscopic controls every 4 years
according to AG screening for gastric cancer risk
[29]. It has been argued that to evaluate the exact
value of surveillance in AG patients and establish
follow-up frequencies, more precise data on the
occurrence of gastric neoplastic lesions, preferably
obtained in large prospective studies with adequate
follow up, are needed [30].
The overall risk of gastric cancer and carcinoids
together has been investigated only in pernicious
anemia patients many years ago [21,22], and recent
studies assessing the overall risk of gastric neoplastic
lesions in AG at long-term follow up are lacking. This
study aimed to investigate the occurrence of gastric
cancerandcarcinoids inaprospectivecohortofpatients
with AG at long-term follow up from 4 years upwards.
Methods
Study population and design
In this study, 200 patients (67% female, median age
55 years, range 22–84 years) with AG with a median
follow up of 7.5 years (range 4–23.4 years) were
included. Inclusion criteria were the presence of
AG and at least one follow-up investigation by gas-
troscopy with biopsies at an interval of at least 4 years
after first diagnosis of AG. Exclusion criteria were
severe chronic comorbidity, making follow-up gastro-
scopies not feasible, and the presence of gastric cancer
at the time of diagnosis of AG.
This study population derived from a prospective
cohort of patients with AG diagnosed between 1992
and 2009, which is included in a surveillance program
for gastric neoplastic lesions [7,23].
The eligible patients numbered 378, of whom dur-
ing follow up 8 (2.1%) died for causes not related to
gastric cancer, 2 (0.5%) had gastric surgery for other
reasons, and 168 (44.4%) were lost at follow up (not
retraceable 30.1%, refused 14.3%). Thus, overall 178
(47.1%) patients of the baseline population dropped
out during follow up and the final follow-up popula-
tion comprised 200 (52.9%) patients with AG. The
main baseline features of the study population are
given in Table I.
At diagnosis of AG, all patients underwent a clinical
interview based on a structured questionnaire to
assess personal and clinical data, family history for
gastric cancer and lifestyle items. All patients were
informed by the way of a specific information sheet
about the increased risk of gastric cancer and type I
gastric carcinoid associated with AG and about the
need to undergo regular follow up by gastroscopy (see
management and follow-up protocol section). The
assumption of proton pump inhibitors was carefully
checked and was withdrawn.
At the time of diagnosis of AG, among the
200 included patients, 4 (2%) type I gastric carcinoids
and 7 (3.5%) noninvasive neoplasias were detected.
In detail, three of the four patients with gastric carci-
noids were female, aged between 40 and 77 years
(median 56.5 years). Three of them had intramucosal
gastric carcinoids and in the fourth patient the gastric
carcinoid was a polyp <1 cm which was removed by
endoscopic polypectomy. Five (71.4%) of the seven
patients with noninvasive neoplasias were female,
aged between 51 and 71 years (median 61 years).
All lesions were low-grade dysplasia, five of them
localized in the antral mucosa without endoscopic
lesions and two of them were corporal adenomatous
polyps (<1 cm) removed by endoscopic polypectomy.
From all patients a written consent was obtained.
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Diagnostic criteria for AG and gastric neoplastic lesions
The diagnosis of AG was based on the histological
confirmation of gastric body atrophy and the presence
of fasting gastrin above upper normal values [31]. All
patients underwent gastroscopy with three biopsies
taken from the gastric antrum (within 3 cm of the
pyloric ring, lesser and greater curve, anterior or
posterior wall) and three biopsies from the mid-
body along the greater curve [15]. In case of lesion,
additional biopsies were obtained. The specimens
were formalin-fixed and routinely processed. About
5 mm thick mucosal gastric sections were stained with
hematoxylin-eosin for routine examination and
Giemsa staining for H. pylori.
According to the updated Sydney System, gastric
body atrophy was defined as focal or complete
replacement of oxyntic glands by metaplastic pyloric
or intestinal glands; this variable was graded on a four-
grade scale represented by absence of replacement
(score 0), replacement to a mild degree (score 1),
moderate degree (score 2), or severe degree (score 3),
as previously reported [32]. Atrophy of the antral
mucosa was defined as focal or complete disappear-
ance of antral glands or their replacement by intestinal
metaplastic epithelium [31].
Serological assays were performed in every patient,
evaluating: fasting serum gastrinemia (normal
value < 40 pg/ml) and immunoglobulin (Ig)G
H. pylori antibodies (normal value < 21 UI/ml).
Gastrin was measured by radioimmunoassay, whereas
H. pylori antibodies IgG were measured by an
enzyme-linked immunosorbent assay commercial
kit (GAP test IgG; Biorad, Milan, Italy). Anemia
pattern was also assessed, evaluating hemoglobin,
mean corpuscolar volume (MCV), ferritin, and vita-
min B12 values. Pernicious anemia was defined as low
hemoglobin concentration, MCV > 100 fl together
with low B12 vitamin levels, responding to intramus-
cular B12 vitamin treatment [33]. Iron-deficiency
anemia was defined as low hemoglobin concentration,
MCV < 80 fl, and ferritin < 30 ng/ml [33].
The definitions of gastric neoplastic lesions (nonin-
vasive neoplasia and gastric cancer) were based on the
Padova International Classification and WHO guide-
lines [34,35]. Diagnosis of type I gastric carcinoid was
performed when enterochromaffin-like cells cell pro-
liferation was >500 m [36], classified according to
WHO 2010 criteria [16].
H. pylori status and treatment
H. pylori status was considered as positive when a
positive H. pylori IgG titer was detected and/or
bacteria were revealed at histology by Giemsa stain
[31]. Bismuth-based triple regimen eradication ther-
apy was prescribed in the case of H. pylori positivity
and, after 6 months, the absence of H. pylori at
histology and a decrease by at least 50% in the initial
titer of H. pylori IgG was the criterion for the suc-
cessful cure of infection [37]. Overall, 97 out of the
112 (86.6%)H. pylori-positive patients were cured of
infection.
Management and follow-up protocol
As shown in (Figure 1), in general, the first follow-up
gastroscopy was scheduled 4 years after diagnosis of
AG during which the same baseline bioptic sampling
was repeated [7,28]. Subsequent follow-up investiga-
tions were scheduled at 4-year intervals with
same bioptic sampling. Endoscopic histological
Table I. Main features of the 200 patients with atrophic gastritis.
Female gender 134 (67)
Age, years, median (range) 55 (22–84)
Overall follow up, years, median (range) 7.5 (4–23.4)
Overall number of follow-up investigations,
median (range)
4 (2–12)
Smoking habit 78 (39)
Presence of pernicious anemia 105 (52.5)
First degree family history for gastric cancer 21 (10.5)
Sydney scores of corporal mucosa
Atrophy
Mild 41 (20.5)
Moderate 40 (20.0)
Severe 119 (59.5)
Intestinal metaplasia
Absent 37 (18.5)
Mild 66 (33.0)
Moderate 66 (33.0)
Severe 31 (15.5)
Helicobacter pylori
Absent 177 (88.5)
Mild 13 (6.5)
Moderate 6 (3.0)
Severe 4 (2.0)
Sydney scores of antral mucosa
Atrophy
Absent 160 (80.0)
Mild 29 (14.5)
Moderate 9 (4.5)
Severe 2 (1.0)
Intestinal metaplasia
absent 171 (85.5)
Mild 18 (9.0)
Moderate 10 (5.0)
Severe 1 (0.5)
Helicobacter pylori
Absent 184 (92.0)
Mild 12 (6.0)
Moderate 3 (1.5)
Severe 1 (0.5)
Data are expressed as total number (%), when not otherwise
reported.
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investigations at shorter intervals earlier than 4 years
after first diagnosis of AG were performed in the case
of H. pylori eradication treatment and diagnosis of
gastric neoplastic lesions. In the case of H. pylori
eradication treatment, gastroscopy/histology was per-
formed at 6 months to evaluate the efficacy of cure
and then patients were monitored by the general
follow-up protocol. If noninvasive neoplasia was
detected, an extensive bioptic sampling of at least
10 biopsies of the gastric mucosa was taken after
6 and 12 months for low-grade noninvasive neoplasia
and after 3, 6, and 12 months for high-grade nonin-
vasive neoplasia [7]. If noninvasive neoplasia was not
confirmed at two following gastroscopies, patients
were followed up by the general follow-up protocol.
When gastric polyps were detected, polypectomy was
performed. Polypoid lesions up to 5 mm were
removed by forceps; otherwise, an electrocautery
snare was used. In the case of a histological diagnosis
of gastric cancer, the indication for mucosectomy and/
or surgery was evaluated. After first diagnosis of type I
gastric carcinoids, gastroscopy with extensive bioptic
sampling after 6 and 12 months was performed. If
type I gastric carcinoid was not confirmed at two
following gastroscopies, patients were followed up
by the general follow-up protocol. All patients with
a diagnosis of type I gastric carcinoids underwent at
least one imaging procedure for the tumor staging
(CT-scan, Octreoscan, Gallium-68 PET scan)
[23,29]. Patients with type I gastric carcinoids were
managed by endoscopic polypectomy and/or
endoscopic/histological surveillance and did not
undergo medical treatments.
However, at any time, when patients referred the
onset of alarm symptoms, such as dysphagia, repeated
vomiting, weight loss, dyspepsia, and/or recent onset
or worsening of iron-deficiency anemia, gastroscopy
was immediately performed.
Data analysis and statistical evaluation
The occurrence of new cases of gastric cancer and
type I gastric carcinoids in AG patients were evaluated
after a follow up of at least 4 years up to the longest
follow up available. Data were expressed as crude
incidence and incidence rate (person-years).
Standard descriptive statistics were expressed as
medians and ranges or absolute counts and percen-
tages. Mann–Whitney and chi-square tests were used
when appropriate. Univariate analysis was performed
to identify patients’ features associated with the pres-
ence of gastric neoplastic lesions at long-term follow
up. Multivariate Cox-regression analysis was per-
formed to identify risk factors for gastric neoplastic
lesions. The incident gastric neoplastic lesions were
coded with value 1 in the binary-dependent variable.
For gastric cancer and dysplasia, the following
features were considered as covariates: age >50 years,
gender, family history for gastric cancer, the presence
of concomitant antral and corporal atrophy, the
presence of intestinal metaplasia in the antrum, the
presence of H. pylori in the corpus, treatment for
H. pylori
positive
H. pylori
negative
H. pylori
negative
Diagnosis of
atrophic gastritis
Type I gastric carcinoid
Noninvasiva neoplasia
Type I gastric carcinoid
Noninvasiva neoplasia
not confirmed
General follow-up protocol
at 4 year-intervals
1° control after 6 mos
2° control after 12 mos
Eradication treatment
1° control after 6–12 mos
Figure 1. Illustration showing the follow-up protocol. Abbreviation: mos = Months.
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H. pylori, and the number of follow-up investigations.
For gastric carcinoids, the following features were
considered as covariates: gender, age <50 years, the
presence of pernicious anemia, the presence of auto-
immune diseases, and fasting gastrin 12-fold over
normal values; however, COX-regression analysis
could not be performed since the covariate pernicious
anemia was present in all patients with gastric carci-
noids. For each covariate, the hazard ratio (HR) and
95% confidence intervals (CIs) are reported. Intervals
between initial AG diagnosis and diagnosis of gastric
neoplastic lesions were analyzed by Kaplan–Meier
analysis. A p-Value of <0.05 was considered statisti-
cally significant. Statistical analyses were run using a
dedicated software (MedCalc Software, Mariakerke,
Belgium, version 12).
Results
During an overall follow up from 4 to 23.4 years
(median 7.5 years) among the 200 included AG
patients, 22 gastric neoplastic lesions were detected,
thus resulting in an overall crude incidence of 11%.
These lesions were diagnosed in 19 (9.5%) patients.
In one female patient, first a type I gastric carcinoid
was detected at 3.5 years and subsequently a gastric
cancer occurred at 5.1 years. In another female
patient, a type I gastric carcinoid was detected at
10.3 years, which recurred at 12 years, and subse-
quently a gastric cancer was diagnosed at 12.5 years.
In Table II, details of patients with gastric neoplas-
tic lesions are shown. Briefly, gastric cancer was
diagnosed in four patients (2 females, aged from
Table II. Main features of atrophic gastritis patients who developed gastric neoplastic lesions at follow up from 4 years upwards.
Age,
years Gender
Endoscopically
visible lesion Site Histology
Occurrence
(years) Treatment
TNM
staging Outcome
Gastric cancer
40 Female No (random
biopsies)
Body Diffuse signet-ring cells
gastric cancer
12.5 Total
gastrectomy
G1N0M0 Free GNL
77 Male Ulcer-like 3 cm Antrum Intestinal-type
adenocarcinoma
6.8 Palliative G1N0M0 Dead
51 Male Ulcer-like 5 cm Antrum Undifferentiated gastric
cancer
7.1 Palliative G3N1M0 Dead
49 Female No (random
biopsies)
Antrum Intestinal-type
adenocarcinoma
5.1 Total
gastrectomy
G1N0M0 Free GNL
Gastric dysplasia
56 Male Multiple polyps
<1 cm
Antrum Low-grade dysplasia 4.9 Polypectomy NA Free GNL
64 Female Irregular mucosa Antrum High-grade dysplasia 13.6 Partial
gastrectomy
NA Free GNL
65 Male No (random
biopsies)
Antrum Low-grade dysplasia 4.8 Monitoring NA Free GNL
58 Female Single polyp 4 cm Body Low-grade dysplasia 19.7 ESD NA Free GNL
58 Female No (random
biopsies)
Antrum Low-grade dysplasia 4.1 Monitoring NA Free GNL
68 Male No (random
biopsies)
Antrum Low-grade dysplasia 4.1 Monitoring NA Free GNL
51 Female No (random
biopsies)
Antrum Low-grade dysplasia 6.3 Monitoring NA Free GNL
Gastric carcinoids
40 Female Single polyp <1 cm
2 polyps <1 cm
Fundus
Body
Type I gastric carcinoid
Type I gastric carcinoid
10.3
12.0
Polypectomy
Polypectomy
NA GC at 12.5 years,
surgery, alive
59 Female 2 polyps <1 cm Body Type I gastric carcinoid 4.0 Polypectomy NA Free GNL
23 Female Single polyp 1 cm Body Type I gastric carcinoid 4.1 Polypectomy NA Free GNL
65 Female No (random
biopsies)
Body Type I gastric carcinoid 4.2 Monitoring NA Free GNL
46 Male Single polyp <1 cm Body Type I gastric carcinoid 6.1 Polypectomy NA Free GNL
54 Female No (random
biopsies)
Body Type I gastric carcinoid 8.5 Monitoring NA Free GNL
69 Male Single polyp <1 cm Body Type I gastric carcinoid 4.0 Polypectomy NA Free GNL
47 Male No (random
biopsies)
Fundus Type I gastric carcinoid 5.5 Monitoring NA Free GNL
34 Female Single polyp <1 cm Fundus Type I gastric carcinoid 15.6 Polypectomy NA Free GNL
49 Female Single polyp <1 cm Body Type I gastric carcinoid 4.0 Polypectomy NA GC at 5.1 years,
surgery, alive
Abbreviations: ESD: Endoscopic submucosal dissection; Free GNL: Free of gastric neoplastic lesions; GC: Gastric cancer; NA: Not
applicable; TNM: T
umor nodes metastasis.
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40 to 77 years, median age 50 years), thus resulting in
a crude incidence rate of 2%. The gastric cancers
occurred at a median follow up of 7.2 years (range
5.1 to 12.5 years) in respect to first diagnosis of AG.
All but three lesions were localized in the gastric
antrum and one was in the body. In regard to histol-
ogy, two cancers were intestinal-type adenocarcino-
mas, one was an undifferentiated gastric cancer and
the fourth was a diffuse signet-ring cell gastric cancer.
In regard to outcome, two patients underwent gastric
surgery and are alive. In the other two patients the
outcome was fatal: in one patient neither surgery nor
other treatments were feasible due to comorbidities
and the other patient experienced a fatal progression
of disease notwithstanding gastric surgery and subse-
quent medical therapy.
Eleven type I gastric carcinoids were detected in
10 patients (9 females, aged from 23 to 69 years,
median age 48 years) with a crude incidence rate of
5.5%. The gastric carcinoids were diagnosed at a
median follow up of 5.1 years (4–15.6 years) in
respect to first diagnosis of AG. In eight cases, the
type I gastric carcinoid presented as a gastric polyp
localized in the body (n = 5) or fundus (n = 3) was
removed by polypectomy, in the remaining two cases
the type I gastric carcinoids were detected by random
biopsies in the fundic mucosa.
In two patients, during further follow up (12.5 and
5.1 years), a gastric cancer was diagnosed.
In the remaining patients (n = 8) no recurrence of
new type I gastric carcinoid or other gastric neoplastic
lesions was observed and, at the longest follow up,
they are all free of neoplastic lesions (median 5.9 years,
range 4–15.5 years).
In seven patients (3 females, aged from 51 to
68 years, median age 58 years), six low-grade gastric
dysplasias and one high-grade dysplasia were found.
These dysplastic lesions occurred at a median follow
up of 7.7 years (range 3.8–19.7 years). All these
lesions were localized in the gastric antrum; in three
cases, the dysplastic lesions were presenting as polyps,
in the remaining cases they were localized on an
endoscopically normal appearing mucosa and were
detected on random bioptic samples. In regard to
outcome, after endoscopic removal of polyps and
monitoring with random biopsies at the longest follow
up of 11.8 years (range 4.1–19.5 years), in none of
these cases a new low-grade or high-grade dysplasia
recurred neither a type I gastric carcinoid occurred.
The one patient with the high-grade dysplasia under-
went partial gastrectomy and is alive.
Given the study population of 200 AG patients with
an overall observation period of 1619.3 years, the
annual incidence rate person-year can be calculated
as 0.25% (95% CI: 0.067–0.63%), 0.43% (95% CI:
0.17–0.89%), and 0.68% (95% CI: 0.34–1.21%) for
gastric cancer, gastric dysplasia, and type I gastric
carcinoids, respectively. The incidence rates of gastric
cancer and gastric carcinoids were similar and not
statistically different from each other (p = 0.0707). For
all gastric neoplastic lesions taken together, the annual
incidence rate person-year can be calculated as 1.36%
(95% CI: 0.85–2.06%).
Hypothetically assuming that first follow up was
scheduled at 3 years according to MAPS guidelines,
four more gastric neoplastic lesions would have been
included (one gastric carcinoid and three gastric dypla-
sias) and this would have increased the overall number
of detected gastric neoplastic lesions to 26 and the
annual incidence rate person-year for all gastric
neoplastic lesions to 1.61% (95% CI: 1.05–2.35).
Risk factors for gastric cancer and carcinoids and
survival by Kaplan–Meier curves
At univariate analysis, patients who developed gastric
cancer or dysplasia at follow up were different from
those free of these lesions for the presence of
concomitant antral and corporal atrophy (58.3% vs.
14.9%, p<0.001), the presenceof intestinalmetaplasia
in the antrum (41.7% vs. 10.3%, p < 0.01), and the
presence of H. pylori in corporal mucosa (33.3% vs.
9.8%, p < 0.05), whereas the presence of pernicious
anemia, positive family history for gastric cancer, age
>50 years, gender, smoking habit or cure of H. pylori
Table III. Risk factors for progression to gastric cancer and/or
dysplasia in multivariate Cox-regression analysis.
Baseline HR multivariate 95% CI
Gender
Male 1.0 1.0
Female 0.8 0.2–2.7
Age
<50 years 1.0 1.0
>50 years 3.1 0.6–14.8
Presence of concomitant antral and corporal atrophy
No 1.0 1.0
Yes 7.2 0.7–68.4
Presence of antral intestinal metaplasia
No 1.0 1.0
Yes 1.2 0.1–12.3
More than 5 follow-up investigations
No 1.0 1.0
Yes 2.7 0.6–11.5
Presence of H. pylori in the corporal mucosa
No 1.0 1.0
Yes 8.05 1.5–43.3
Cure of H. pylori infection
No 1.0 1.0
Yes 0.3 0.1–1.2
Significant risk factors are in bold typeface.
Abbreviations: CI = Confidence interval; HR = Hazard ratio.
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were not different between the two groups. The num-
ber of follow-up investigations was higher in the group
with lesions (p < 0.001). As shown in (Table III), the
presence ofH. pylori in the gastric corpus is a risk factor
for gastric cancer and dysplasia (Cox regression anal-
ysis: HR 8.05 (95%CI 1.5 to 43.3)).
Performing a subgroup analysis per first-degree
family history for gastric cancer, it emerged that
gastric neoplastic lesions were more frequent (nearly
two-fold) among patients with positive family history
compared to those without first-degree relatives with
gastric cancer, albeit statistical significance was not
reached (23.5% vs. 12.6%, p = 0.4867).
Stratifying patients per successful treatment of
H. pylori infection, no difference between groups
was observed: in the group of not-cured patients,
two patients developed gastric dysplasia and none
developed gastric cancer (data not shown).
Patients who developed gastric carcinoids at follow
up were characterized by the presence of pernicious
anemia which was present in all of them compared to
50.6% of those without carcinoids (p < 0.01) and the
absence of antral and/or corporalH. pylori at histology
compared to 12.4% in those without carcinoids, albeit
not statistically significant (p = 0.4670). Other features
as age <50 years (60% vs. 38.6%), female gender (70%
vs. 67%), co-presence of autoimmune diseases (80%
vs. 50.6%), positivity to anti-parietal cell antibodies
(100% vs. 72%) or gastrin values 12-fold over normal
values (80% vs. 52.3%) were similar in the two groups.
In regard to gastric cancer and gastric carcinoids,
the mean overall survival time (95% CI for the mean)
free of lesions was 22.7 (21.9–23.4) years and
21.6 (20.5–22.8) years, respectively. Kaplan curves
are shown in Figure 2.
Retrospective post-hoc analysis based on operative link
for gastritis assessment and operative link for intestinal
metaplasia staging system
Based on operative link for gastritis assessment
(OLGA) and operative link for intestinal metaplasia
(OLGIM) staging system, we performed a retrospec-
tive post-hoc analysis in order to understand whether
patients who developed gastric cancer or dysplasia at
follow up had higher OLGA or OLGIM stages
compared to those who remained free of lesions
during follow up.
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Figure 2. Kaplan–Meier survival curves showing the survival time in years free of gastric cancer (A) and free of gastric carcinoids (B). Baseline
cumulative hazard function.
Table IV. Retrospective post-hoc analysis of OLGA and OLGIM
staging system.
Presence of
gastric cancer
or dysplasia;
n = 11
Absence of
gastric cancer
or dysplasia;
n = 189 p
OLGA staging 0.0141 (chi-
square
test for trend)
Stage 0 0 0
Stage 1 2 (18.2) 37 (19.6)
Stage 2 4 (36.3) 131 (69.3)
Stage 3 3 (27.3) 15 (7.9) 0.0046
Stage 4 2 (18.2) 6 (3.2)
OLGIM staging 0.2285
(chi-square -
test for trend)
Stage 0 2 (18.2) 32 (16.9)
Stage 1 3 (27.3) 62 (32.8)
Stage 2 3 (27.3) 86 (45.5)
Stage 3 2 (18.2) 6 (3.2) 0.0163
Stage 4 1 (9.1) 3 (1.6)
Abbreviations: OLGA = Operative link for gastritis assessment;
OLGIM = Operative link for intestinal metaplasia assessment.
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In regard to OLGA, stages 1, 2, 3, and 4 were
present at baseline in 19.5%, 67.5%, 9%, and 4% of
patients, respectively. In regard to OLGIM, stages 0,
1, 2, 3, and 4 were present at baseline in 17%, 32.5%,
44.5%, 4%, and 2%, respectively. As shown
in Table IV, gastric epithelial neoplastic lesions
occurred at follow up more frequently in patients
who had stages 3 and 4 by OLGA and OLGIM
staging at baseline (p < 0.05). Analyzing OLGA
and OLGIM staging in the four patients who devel-
oped gastric cancer at follow up, we observed that
three had stage 2 and one had stage 4 by OLGA,
whereas one had stage 0, one had stage 1, one had
stage 2, and one had stage 4 by OLGIM.
Discussion
This prospective long-term follow-up study from
4 years upwards to more than 20 years showed an
annual incidence rate person-year of 0.25% for gastric
cancer in AG patients. Previously we reported a
similar annual incidence rate person-year of 0.2%
for gastric cancer at a median follow up of 4.3 years
in 300 AG patients [7]. Another study detected, by
yearly endoscopy over 10 years, 14 (8.4%) gastric
cancers in 166 patients with dysplasia, intestinal meta-
plasia, AG, and in AG and intestinal metaplasia the
risk of malignancy was 11% [5]. According to Glo-
bocan 2012, the annual incidence rate for gastric
cancer in the general Italian population is estimated
to be 0.004% [38]. This study, thus, confirms the
increased risk of gastric cancer in AG.
The findings of this study further showed an annual
incidence rate person-year of 0.7% for type I gastric
carcinoids. This figure was nearly twofold compared
to a previous study, in which an annual incidence rate
person-year of 0.4% for these tumors was reported at
a median follow up of 6.3 years [23]. Previous data on
type I gastric carcinoids incidence focused on perni-
cious anemia patients only and are therefore not
directly comparable to our findings. A 1998 study
described eight new cases of type I gastric carcinoids
in 416 patient-years corresponding to an annual inci-
dence rate of 2% [21]. From a 1988 study, after
1397 patient-years, an annual incidence rate of
0.1% of type I gastric carcinoids can be calculated
[22]. This higher incidence rate of type I gastric
carcinoids might be due to the longer follow-up
period which was increased up to a median of
7.5 years. However, the incidence of type I gastric
carcinoids has been on the rise for over the past
30 years, as have all that of other neuroendocrine
tumors. This may be the consequence of a true
increase of tumor incidence, but it may also reflect
an increased detection of these tumors due to more
advanced diagnostic methods [39].
This study showed that in AG patients, at long-
term follow up, the annual incidence rate person-year
for all gastric neoplastic lesions taken together can
be calculated to be as high as 1.36%. Formerly
only patients with pernicious anemia have been inves-
tigated at varying follow-up periods
[21,22,24–26]. Considering that the estimated bur-
den of AG in the general population is up to 30%,
according to a recent systematic review [40], a sub-
stantial number of persons may be at higher risk of
gastric neoplastic lesions. Applying the prognostic
staging systems OLGA and OLGIM, from this study,
a significant higher frequency of stages 3 and 4 among
patients with gastric cancer and dysplasia compared to
those without (p < 0.001) emerged, suggesting the
utility of this staging system with the limits of the
retrospective post-hoc analysis.
From this study, another new result emerged: the
incidence rates of gastric cancer and type I gastric
carcinoids were not different (p = 0.07), indicating
that AG patients are similarly exposed to both risks.
The finding that, over time, two female patients devel-
oped first type I gastric carcinoids and subsequently at
long-term follow-up gastric cancer further support the
exposition to the double risk of gastric neoplastic
lesions in AG. This risk is present in AG due to the
pathophysiological changes related to gastric body
atrophy, such as increased pH, reduced ascorbic
acid, and scavenging of nitrites and other potential
carcinogenic substances [41]. In recent years, it
became apparent that besides H. pylori, other bacteria
may be involved in gastric carcinogenesis; it has been
shown that the gastric cancer microbiota was domi-
nated by species of the genera Streptococcus, Lactoba-
cillus,Veillonella, andPrevotella; albeit, the roles of these
species in thedevelopment of gastric cancerneeds tobe
determined [42]. Hypergastrinemia due to atrophy of
oxyntic mucosa in AG is well known as a major path-
ogenetic factor for type I gastric carcinoids, because
gastrin acts as a growth factor for enterochromaffin-like
cells [17–19]. Hypergastrinemia has been proposed in
many animal models of gastric carcinogenesis; in all
species where long-term hypergastrinemia has been
induced, an increased risk of gastric malignancy,
with adenocarcinoma phenotype and even the
signet-ring cells phenotype, was observed [43,44].
This study further showed that the patients’ features
associated with gastric cancer and type I gastric carci-
noids were different, keeping in step with the different
pathogenetic mechanisms of these two type of tumors
[3,10–12,17–19]. The occurrence of type I gastric
carcinoids and the survival free of gastric carcinoids
was strongly linked to pernicious anemia, present in all
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cases who developed this neuroendocrine neoplasia.
Also, gastric autoantibodieswere present in all patients
with type Igastric carcinoids.These results suggest that
type I gastric carcinoids are mainly associated with
features of autoimmune gastritis. Gastric cancer,
instead, was associated with the presence of H. pylori
in the corporal mucosa (HR = 8). This finding keeps in
step with the concept of corpus-predominant gastritis
supporting the observations of Uemura et al. of more
than 10 years ago that gastric cancer develops in
H. pylori-positive patients and in those with severe
gastric atrophy, corpus-predominant gastritis or
intestinal metaplasia are at increased risk [10].
In our study the regular follow-up investigations
permitted to successfully treat all patients with type I
gastric carcinoids and two out of four gastric cancers.
The fatal outcome of one gastric cancer patient was
mainly related to his comorbidities rather than to the
stageatwhichgastriccancerwasdiagnosed.Inregardto
type Igastric carcinoids, all lesionshadbenignbehavior
and could be endoscopically treated, avoiding gastric
surgery in all cases. These findings raise the question of
the benefit of regular endoscopicmonitoringwith stan-
dard bioptic mapping of antral and corporal mucosa in
thesepatients inorder todetect andproperly treat type I
gastric carcinoids, gastric dysplasia or cancer.
The present study has some strengths, as the pro-
spective inclusion of patients with standardized diag-
nostic criteria for AG, the follow-up protocol, and
long-term cohort study, but we are aware of some
limits, as the long inclusion period, the relative small
sample size, and the possible lack of generalizability of
our results due to epidemiological differences in
populations (i.e. East–West), in particular with regard
to gastric cancer [45]. Another weakness is the relative
high rate of lost at follow up which might have led to
an underestimation of incidence rates of gastric can-
cer and carcinoids in this long-term follow-up cohort.
In conclusion, this study shows an annual incidence
rate of 1.36% person-year for gastric neoplastic
lesions in AG patients at long-term follow up. AG
patients are similarly exposed to gastric cancer and
type I gastric carcinoids.
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